January 31, 2017 — Check-Cap Ltd. recently announced the enrollment of the first patient in its multi-center study of the C-Scan system in support of its CE Mark submission.
C-Scan employs proprietary, ultra-low-dose X-ray technology in an ingestible capsule to create a 3-D map of the inner colon to detect polyps, which may be, or may become, cancerous. Unlike existing imaging modalities, Check-Cap's approach does not require bowel preparation, which is a significant obstacle to screening, according to the company. Designed to improve the patient experience and maximize the number of people who complete screening, C-Scan works in concert with the natural functioning of the colon, and does not require sedation or changes to diet and normal daily activities.
The current multi-center, prospective trial, designed to demonstrate the safety and clinical performance of C-Scan, will evaluate polyp detection as compared to colonoscopy. Check-Cap expects to submit for a CE Mark in the first half of 2017.
The company also plans to initiate a pilot trial in the United States in the second half of 2017, according to Check-Cap CEO Bill Densel.
For more information: www.check-cap.com